In the last trading session, 5.52 million TG Therapeutics Inc (NASDAQ:TGTX) shares changed hands as the company’s beta touched 2.19. With the company’s per share price at $12.07 changed hands at $0.81 or 7.19% during last session, the market valuation stood at $1.83B. TGTX’s last price was a discount, traded about -195.53% off its 52-week high of $35.67. The share price had its 52-week low at $6.46, which suggests the last value was 46.48% up since then. When we look at TG Therapeutics Inc’s average trading volume, we note the 10-day average is 5.08 million shares, with the 3-month average coming to 5.28 million.
TG Therapeutics Inc (NASDAQ:TGTX) trade information
Instantly TGTX was in green as seen at the end of in last trading. With action 18.10%, the performance over the past five days has been green. The jump to weekly highs of 12.10 on Friday, 11/17/23 added 7.19% to the stock’s daily price. The company’s shares are showing year-to-date upside of 2.03%, with the 5-day performance at 18.10% in the green. However, in the 30-day time frame, TG Therapeutics Inc (NASDAQ:TGTX) is 80.69% up. Looking at the short shares, we see there were 37.02 million shares sold at short interest cover period of 8.06 days.
The consensus price target for the stock as assigned by Wall Street analysts is $27.81, meaning bulls need an upside of 56.6% from its current market value. According to analyst projections, TGTX’s forecast low is $6.00 with $41.00 as the target high. To hit the forecast high, the stock’s price needs a -239.69% plunge from its current level, while the stock would need to tank 50.29% for it to hit the projected low.
TG Therapeutics Inc (TGTX) estimates and forecasts
Data shows that the TG Therapeutics Inc share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -59.70% over the past 6 months, a 101.37% in annual growth rate that is considerably higher than the industry average of 14.10%. Moreover, analysts have looked to higher expectations by upgrading its fiscal year 2023 revenue estimates. The rating firms predict current quarter revenue for TG Therapeutics Inc will rise 69.20%, while the growth in revenue is estimated to hit 67.90% for the next quarter. Year-over-year growth is forecast to reach 8,138.10% up from the last financial year.
Consensus estimates given by 7 financial analysts project the company’s revenue in the current quarter to hit an average of $38.68 million. 3 analysts are of the opinion that TG Therapeutics Inc’s revenue for the quarter ending Mar 2024 will be $43.39 million. The company’s revenue for the corresponding quarters a year ago was $80k and $7.8 million respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 48,250.00%. The estimates for the next quarter sales put growth at 456.10%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 5.17%. The 2023 estimates are for TG Therapeutics Inc earnings to increase by 96.42%.
TG Therapeutics Inc is expected to release its next quarterly earnings report on November 01.
TG Therapeutics Inc (NASDAQ:TGTX)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 8.59% of TG Therapeutics Inc shares while 64.76% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 70.85%. There are 64.76% institutions holding the TG Therapeutics Inc stock share, with Vanguard Group Inc the top institutional holder. As of Jun 29, 2023, the company held 8.91% of the shares, roughly 13.46 million TGTX shares worth $334.22 million.
Blackrock Inc. holds the second largest percentage of outstanding shares, with 6.57% or 9.92 million shares worth $246.35 million as of Jun 29, 2023.
Among Mutual Funds, the top two as of Jun 29, 2023 were Vanguard Total Stock Market Index Fund and Vanguard Small-Cap Index Fund. With 4.28 million shares estimated at $106.28 million under it, the former controlled 2.83% of total outstanding shares. On the other hand, Vanguard Small-Cap Index Fund held about 2.30% of the shares, roughly 3.47 million shares worth around $86.22 million.